Evidence map›Paper›PMID 41442664›Full record

Trial reportJMIR mHealth and uHealth2025

Effect of a Mobile Health Intervention in the Management of Hypertension: Open-Label Cluster-Randomized Trial.

Xiaoli Zhao, Qiang Zhao, Qinxian Yang, Yan Li, Xiaona Xing, Xiaoping Li

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in JMIR mHealth and uHealth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaoli Zhao *Department of Cardiology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, No. 32, Section 2, Yihuan Road, Qingyang District, Chengdu, Sichuan, 610072, China, 86 18011159771.ORCID 0000-0002-3502-4155
Qiang Zhao *Department of Ultrasound Medicine, Guangyuan Traditional Chinese Medicine Hospital, Guangyuan, Sichuan, China.ORCID 0009-0009-9564-3829
Qinxian Yang *Department of Endemic Diseases and Vector Control, Guangyuan Lizhou District Center for Disease Control and Prevention, Guangyuan, Sichuan, China.ORCID 0009-0000-6321-8742
Yan LiDepartment of Geriatrics, Guangyuan Wan Yuan Hospital, Guangyuan, Sichuan, China.ORCID 0009-0000-1341-012X
Xiaona XingDepartment of Geriatrics, Chengdu Wenjiang District People's Hospital, Chengdu, Sichuan, China.ORCID 0009-0003-5481-9142
Xiaoping LiDepartment of Cardiology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, No. 32, Section 2, Yihuan Road, Qingyang District, Chengdu, Sichuan, 610072, China, 86 18011159771.ORCID 0000-0001-5580-5605

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Digital therapeutics represents a promising approach to support the management of hypertension. Rural regions in China face substantial challenges in hypertension prevention and management. Given the rapid growth in use of the internet and mobile technologies, particularly smartphones, we developed a user-friendly WeChat mini-program "E-controlled pressure (eKongya)" to assist village physicians in managing patients with hypertension. Objective: This trial aimed to investigate the efficacy of digital interventions for blood pressure (BP) control in patients with hypertension. Methods: This open-label cluster-randomized controlled study was conducted in 8 villages in China. Individuals with systolic BP (SBP) ≥140 mm Hg or diastolic BP (DBP) ≥90 mm Hg were recruited. Eight villages were randomly assigned in a 1:1 ratio to the digital intervention group or control group. The primary end point was the hypertension control rate at 24 weeks among the study participants. The secondary end points were the changes in mean SBP and DBP from baseline to 24 weeks. All analyses were performed using the full analysis set. Results: Between June and July 2024, a total of 95 participants were enrolled and allocated to the digital intervention group (n=48, 51%) or the control group (n=47, 49%). After 24 weeks, data were available from 87 (92%) participants, and the mean age was 63.8 (SD 9.7) years, with 48% (n=42) being female participants. The digital intervention group (25/44, 57%) had a higher percentage of participants with controlled BP compared to the control group (21/43, 49%), although this difference was not statistically significant (P=.60). Logistic regression analysis showed that the digital interventions did not significantly increase the hypertension control rate (odds ratio 0.73, 95% CI 0.31-1.69; P=.46). In the intervention group, SBP decreased from 158.0 (SD 18.4) mm Hg at baseline to 137.5 (SD 13.0) mm Hg at 24 weeks and DBP decreased from 93.8 (SD 10.3) mm Hg to 85.3 (SD 11.6) mm Hg. In the control group during that same period, SBP decreased from 161.1 (SD 18.2) mm Hg to 139.6 (SD 13.2) mm Hg, and DBP decreased from 99.2 (SD 9.2) mm Hg to 83.4 (SD 12.1) mm Hg. After adjusting for baseline SBP or DBP, the mean change from baseline to 24 weeks was comparable between the digital intervention and control groups for both SBP (between-group difference -1.6, 95% CI -7.2 to 3.9; P=.56) and DBP (between-group difference 3.3, 95% CI -1.8 to 8.5; P=.21). No major program-related safety events occurred up to 24 weeks. Conclusions: Our study demonstrated that the digital interventions increased the hypertension control rate in rural areas, although this improvement was not statistically significant. Nevertheless, providing convenient BP measurements and health education to these patients notably enhanced hypertension control rates.

Indexed as

HypertensionAdultAgedChinaFemaleHumansMaleMiddle AgedMobile ApplicationsTelemedicineblood pressure monitoringChinadigital interventionhealth educationhypertension controlhypertension managementmobile phoneonline consultationrural areassmartphoneWeChat mini-program

Identifiers

PMID41442664
PMCPMC12735645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.